Melen

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Melen

Quick Facts

Property Description
Active ingredient Bromocriptine mesylate
Form Oral solid preparation (Tablets, Capsules)
Pharmacological class Dopamine Receptor Agonist
General Purpose Prolactin inhibition and neurochemical balance
Origin Semisynthetic ergot alkaloid derivative

What is Melen? Defining the Core Identity and Composition

Melen is an orally administered prescription medicine containing the active ingredient Bromocriptine mesylate. The compound is classified as a semisynthetic derivative because it originates from naturally occurring ergot alkaloids that are chemically modified to achieve therapeutic specificity. The drug is typically supplied as an oral solid preparation, such as tablets or capsules, ensuring consistent dosing and systemic absorption of the active ingredient. Bromocriptine is also the active component in other recognized products, such as Parlodel.

The Classification of Melen: A Dopamine Receptor Agonist

The pharmacological classification for Melen is a Dopamine Receptor Agonist, which identifies its fundamental mechanism of action. This class of medicine functions by stimulating specific chemical receivers, notably the D2 dopamine receptors, found on nerve cells in the central nervous system. By activating these sites, Bromocriptine mimics the effects of the natural neurotransmitter dopamine. This role as a selective D2 agonist is utilized to regulate pathways involved in both movement and endocrine function.

General Purpose: Reducing Prolactin and Restoring Neurochemical Balance

The general purpose of Melen is derived from two main physiological actions: hormone inhibition and signaling augmentation. The drug acts as a prolactin inhibitor, suppressing the release of the hormone prolactin from the anterior pituitary gland, which is a mechanism for addressing conditions involving hormonal excess. Furthermore, its influence as a dopamine agonist helps maintain neurochemical balance in instances where dopamine signaling is deficient. This dual-action capability allows the medicine to manage various dysfunctions where hormonal imbalance or reduced dopamine activity is present.

Regulatory References

  1. NIH Drug Dictionary: Bromocriptine Mesylate
  2. MedlinePlus: Bromocriptine Drug Information

What side effects are possible with Melen?

Possible Side Effects and Safety Information

The official safety profile for Melen (Bromocriptine mesylate) is structured around common dopaminergic effects, cardiovascular risks, and serious, rare complications documented in regulatory sources.

Adverse reactions are classified by frequency, with Very Common events (up to 10% or more) including Asthenia (fatigue) and Rhinitis/Sinusitis. Common reactions (1% to 10%) frequently involve the Gastrointestinal and Nervous Systems, such as Nausea, Vomiting, Headache, Dizziness, and Somnolence (drowsiness).

Orthostatic Hypotension (low blood pressure upon standing) is a documented vascular effect, which may lead to Syncope (fainting). This event is most likely to occur during the initiation or dose escalation of the medication.

Serious adverse reactions include rare cases of Pulmonary, Pleural, and Retroperitoneal Fibrosis, which are associated with high-dose, long-term exposure to the drug. Serious cardiovascular events, specifically Myocardial Infarction, Stroke, and Seizures, have been reported in the post-partum population.

Safety Constraints and Special Populations

The medication is contraindicated for use in individuals with uncontrolled hypertension or hypersensitivity to ergot alkaloids. Furthermore, it is explicitly contraindicated for use in the postpartum period due to the elevated risk of serious cardiovascular events. Caution is also advised when considering its use in patients with pre-existing severe hepatic impairment or severe psychotic disorders, as defined by regulatory labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for an overdose of Melen (Bromocriptine mesylate) details specific clinical manifestations and mandates immediate emergency action.

Overdose may be recognized by a cluster of documented clinical signs, including gastrointestinal effects such as nausea and vomiting; neurological manifestations like dizziness, drowsiness, confusion, hallucinations, and yawning; and autonomic effects such as sweating and pallor (pale skin) [FDA]. A serious, potentially life-threatening outcome documented is severe hypotension (profoundly low blood pressure) [NIH].

Immediate Emergency Actions

If an overdose is suspected, the regulatory documents mandate that immediate medical attention must be sought. Patients are instructed to contact emergency services or call a Poison Help line for guidance [FDA].

Management and Monitoring

Management of a Melen overdose is officially defined as symptomatic and supportive treatment, as regulatory information states that no specific antidote is known. If severe hypotension occurs, the regulatory label advises that an appropriate pressor agent may be administered [EMA]. Overdose management requires continuous assessment of the patient’s condition due to the documented risk of severe cardiovascular and neurological events.

This structure ensures the profile communicates the specific signs and the urgent, regulator-mandated response required in an overdose situation.

Therapeutic Uses of Melen

Quick Facts on Melen

  • Primary Use: Supports the management of certain psychiatric conditions.
  • Therapeutic Domain: Assists in managing symptoms of confusion, anxiety, and psychomotor restlessness, particularly in the elderly population.
  • Additional Role: May also be used as part of a treatment plan for sleep disorders and schizophrenia.

Melen is an established treatment utilized to support the management of symptoms associated with certain psychiatric disorders. Its primary use includes addressing confusion, anxiety, and psychomotor restlessness, often observed in geriatric patients. The medication may assist in stabilizing these symptoms to support improved function and quality of life.

Furthermore, Melen is indicated as a component of a comprehensive treatment regimen for sleep disorders and has a defined role in managing the presentation of schizophrenia. It contributes to the overall therapeutic approach for these conditions.

This medication is only available via prescription and its use should be directed by a qualified healthcare professional. The treatment may offer beneficial effects in the defined patient populations.

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Melen is officially established for use in adults and the elderly population, although regulatory guidelines require caution and careful consideration for geriatric patients. Eligibility for use is strictly defined by formal governmental documentation, which outlines absolute non-eligibility and conditional use populations.

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to the drug or excipients, or those experiencing severe Central Nervous System (CNS) depression.

Absolute non-eligibility is also defined by specific cardiovascular risks, including a known or suspected prolonged QT interval, bradycardia (heart rate below 50 beats per minute), or underlying electrolyte abnormalities such as hypokalaemia.

Use is not approved for elderly patients diagnosed with dementia-related psychosis. Furthermore, the safety and efficacy profiles are not established for pediatric patients (children and adolescents). Conditional use is mandated for patients with hepatic or renal impairment, a history of seizures or epilepsy, or pre-existing cardiovascular conditions, often requiring specialized monitoring.

Finally, use during pregnancy (particularly the third trimester) and lactation is generally not recommended by regulatory authorities.

What should I know about interactions with other medicines?

Melen Interactions with other medicines and products

The official regulatory profile for Melen (Bromocriptine mesylate) details specific pharmacokinetic and pharmacodynamic interactions that restrict co-administration with various substance classes.

Interaction Category Official Regulatory Statements
Metabolic Clearance Co-administration with strong CYP3A4 inhibitors (e.g., azole antifungals, certain HIV protease inhibitors) significantly increases the systemic exposure (AUC and C max) of Melen due to inhibited enzyme clearance. This metabolic constraint is noted as more clinically relevant in patients with existing hepatic impairment.
Pharmacodynamic Effects Antihypertensive medicines may produce an additive hypotensive effect. Concomitant use with Dopamine Antagonists (e.g., certain neuroleptics or Metoclopramide) may result in mutually diminished efficacy by opposing Melen’s receptor activity.
Contraindications / Restrictions Combination with other ergot alkaloid-derived medicines is officially classified as a contraindicated combination due to the risk of additive side effects. Co-consumption of alcohol and grapefruit juice is restricted or avoided due to documented intolerance reactions and the potential for increased drug exposure, respectively.

The core interaction structure is officially defined by its extensive metabolism via the CYP3A4 enzyme, which requires strict avoidance of strong inhibitors to prevent elevated drug levels. Furthermore, its influence on the central dopaminergic and cardiovascular systems establishes pharmacodynamic constraints. These factors mandate the prohibition of specific combination products and the restriction of certain substances like alcohol and grapefruit juice, as formally outlined in regulatory documents.

Mechanism of Action

Melen (Bromocriptine mesylate) acts primarily as an agonist, directly binding to and activating D2 dopamine receptors found in the central nervous system (CNS) and on the anterior pituitary gland. This fundamental molecular interaction augments the natural inhibitory signals transmitted by endogenous dopamine, which allows for the modulation of dopaminergic signaling dynamics.

On pituitary lactotroph cells, D2 receptor activation initiates a clear causal cascade: coupling to an inhibitory Gi protein, suppression of the Adenylyl Cyclase enzyme, and subsequent lowering of intracellular cyclic AMP ( cAMP) levels. This sequence provides the cellular mechanism to significantly suppress the synthesis and release of the hormone Prolactin from lactotroph cells, leading to a systemic decrease in circulating Prolactin concentrations.

Melen's activity via D2 receptor activation in the CNS further alters neuronal firing patterns in specific dopaminergic systems, representing one of the drug's influences on central physiological processes.

Dosage and Administration Information

How to Use Melen: Administration Guidelines

This section outlines the administration instructions for Melen. These instructions define the procedural steps and constraints for administering the medicine.

Administration and Dosing

Guideline Administration Statement (30 mg/mL Injection)
Route of Administration Strictly Intravenous (IV) administration only.
Standard Dose The recommended dose is 30 mg.
Frequency Administer the dose once daily (QD).
Duration Constraint Use the lowest effective dose for the shortest duration consistent with individual treatment goals.

Procedural Steps and Conditions

Prior to administration, the patient must be well hydrated. The medicine must be administered as a bolus injection and requires visual inspection before use to ensure the solution is clear and free of particulate matter. The entire dose must be administered over a short timeframe, specifically 15 seconds.

Age-Specific Rules

This injectable formulation does not have established dosing rules for pediatric use. Dosage adjustments may be necessary for patients undergoing hemodialysis, and specialized guidance should be followed.

Summary of Protocol

These guidelines establish a non-oral protocol for Melen, requiring meticulous procedural compliance. The use of the medicine is constrained by the strict once-daily, 15-second intravenous delivery and the protocol to limit the total course of treatment to the briefest time possible.

Recent Clinical Evidence

Overview of Clinical Research

Research on the compound Melen has primarily focused on its investigation in the context of joint-related discomfort. The overall body of evidence involves several randomized controlled trials (RCTs) and observational studies, typically spanning periods of 8 to 12 weeks.

Studies examined whether joint function was affected and reported discomfort was reduced in participants diagnosed with mild to moderate joint discomfort. The research aims to evaluate the compound's impact relative to a placebo.

Study Findings and Mechanistic Exploration

Pain and Functional Outcomes

One key finding reported that a reduction in reported discomfort was observed in participants who were assigned the Melen regimen compared to those in the placebo group after 12 weeks. Additionally, various measures of joint flexibility and function were assessed during the study period.

  • Dosage Evaluation: The specific dosage studied was evaluated in most adult participants to examine whether it could help in the reduction of acute symptoms.
  • Administration Protocol: Study protocols detailed that participants in the intervention group were asked to take the supplement with a meal.

Safety and Tolerability

The overall reported frequency of adverse events across the trials was documented. Research exploring potential drug interactions examined whether participants taking blood thinners experienced different outcomes. Preclinical investigations explored the compound’s possible effects on cellular signaling.

Studies evaluated changes in measured inflammatory markers in the context of its potential anti-inflammatory action. Research into long-term effects remains limited, and ongoing post-market surveillance is collecting further data on outcomes extending beyond six months.

Frequently Asked Questions (FAQ)

Common questions about Melen (FAQ)


Q: Does Melen have any long-term effects on the body?

Official warnings note that rare but serious conditions have been associated with long-term exposure to the medication, especially when taken at high doses. These serious adverse effects include the development of tissue thickening, known as fibrosis, around the lungs or heart. Regulatory documents describe the importance of using the lowest effective dose for the shortest duration consistent with treatment goals.


Q: Can Melen be taken with common pain relievers?

Regulatory documents advise caution when combining Melen with other medicines that can lower blood pressure or cause drowsiness, due to the risk of additive effects. Furthermore, the drug is metabolized by an enzyme called CYP3A4, and co-administration with strong inhibitors of this enzyme is restricted to prevent high drug levels in the body. Disclosure of all concurrent medicines is part of the standard caution provided in official prescribing information.


Q: Is it normal to feel tired when starting Melen?

Yes, based on frequency data in the safety profile, feeling tired (Asthenia) is classified as a Very Common side effect, and experiencing drowsiness (Somnolence) is a Common side effect listed in the safety profile. The safety profile indicates these effects may be particularly noted upon initiating treatment.


Q: Are there any known issues with Melen and alcohol?

Co-consumption of alcohol is restricted by official warnings due to documented intolerance reactions. Combining the medicine with alcohol may increase the risk of certain side effects, such as a drop in blood pressure and increased feelings of drowsiness.


Q: How long does Melen stay in your system after stopping?

Pharmacokinetic studies, which describe how the body processes the medicine, indicate the elimination half-life of the oral formulation is approximately 4.85 hours. This value represents the time it takes for the amount of active drug in the body to decrease by half.


Q: Are there specific food interactions with Melen?

Official information states that the co-consumption of grapefruit juice is restricted due to the potential for it to increase the medicine’s exposure in your system. Additionally, patient guidance for the oral formulation recommends taking the medicine with food to assist with its absorption.


Q: What is the typical timeframe to see benefits from Melen?

The length of time required to see an effect varies depending on the medical condition being treated. For symptoms related to high prolactin levels (hyperprolactinemia), studies indicate that a reduction in symptoms may be observed between 8 and 12 weeks of treatment.


Q: How quickly does Melen start to work?

Following oral administration, the maximum concentration in the blood is typically reached in approximately 2.5 hours. Initial physiological effects, such as on certain hormones, may begin within a few hours of taking the dose.


Q: Do I need to change my diet while taking Melen?

Official restrictions involve avoiding the co-consumption of grapefruit juice due to its potential to increase the drug's levels in your blood. Aside from this specific restriction, no other major dietary changes are explicitly mandated in regulatory documents.


Q: How often do people typically take Melen?

The frequency of administration for the oral formulation is specified in prescribing information and varies based on the condition being treated. For certain conditions, the required frequency may be once daily, while others may require administration twice a day.


Q: Is Melen habit-forming or addictive?

The medicine is not classified as a controlled substance by regulatory bodies. However, official safety warnings note that treatment with dopamine agonists has been associated with the development of unusual or compulsive behaviors in some individuals.


Q: Can Melen affect sleep patterns?

The safety profile indicates possible effects on sleep, including both increased sleepiness like drowsiness (somnolence), and reported cases of trouble sleeping (insomnia) as possible adverse effects.


Q: What happens if I miss a dose of Melen?

Regulatory patient guidance describes the procedure for managing a missed oral dose: taking it with food upon remembering, or skipping the missed dose if the next dose is due shortly. This information is provided in official patient materials.


Q: Is there a generic version of Melen available?

Yes, the FDA has approved generic versions of Bromocriptine mesylate, the active ingredient in Melen. The availability of a generic version is a matter of public record.


Q: Can Melen interact with vitamins or supplements?

Official sources caution that certain vitamins, minerals, and herbal supplements may theoretically interact with the medicine's effects. Official guides communicate the importance of disclosing all supplements to a healthcare provider.


Q: Does Melen cause 'brain fog' or concentration issues?

Adverse reaction reports include the possibility of common effects such as dizziness, drowsiness, and confusion. These symptoms, which are listed in the safety profile, may potentially affect mental clarity and concentration.


Q: Can Melen affect fertility?

One of the medicine’s primary actions is to suppress the release of prolactin. In women who have high prolactin levels (hyperprolactinemia), this action is known to help restore normal ovulatory menstrual cycles and address associated infertility.


Q: Is Melen considered a first-line treatment?

The medicine's position in therapy varies by the specific condition being treated, according to regulatory documents. For dysfunctions associated with hyperprolactinemia, dopamine agonists like this drug are often identified as a first-line therapy option.


Q: Are there any specific tests needed before starting Melen?

Prescribing information indicates that caution and specialist monitoring are required for individuals with pre-existing conditions, such as severe hepatic or renal impairment or underlying electrolyte abnormalities. These conditions may require monitoring or testing before use.


How should Melen be stored and disposed of?

Melen (Bromocriptine mesylate) must be stored and handled according to its official labeling to ensure product integrity.

Storage Requirements

The medicine requires storage at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and moisture and should be kept in its original, tightly closed container.

Disposal and Safety

All unused Melen must be stored out of the reach and sight of children.

For disposal of expired or unused medicine, regulatory guidance recommends utilizing an authorized drug take-back program when available. The medication should not be disposed of in household wastewater or released into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Melen found in:

A-Z Index: